# US 2012/0258911 A1 · Phenylalkylcarboxylic acid delivery agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258911 A1
- Document ID: US20120258911A1
- Status: Published application
- Kind: A1
- Application number: 13/474,491
- Filed: 2012-05-17
- Published: 2012-10-11
- Earliest claimed: 2007-02-08
- Assignees: Emisphere Technologies, Inc.
- Inventors: David Gschneidner; Stephen V. Pusztay
- Web page: https://patentgrep.com/patent/US20120258911A1

## CPC

- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 7/06: Antianaemics
- A61P 9/08: Vasodilators for multiple indications
- A61P 19/10: for osteoporosis
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.

## Claims

### Claim 1

A composition comprising:
(A) at least one biologically active agent; and
(B) at least one delivery agent compound represented by formula I
or a pharmaceutically acceptable salt thereof, wherein
R1-R5 are independently hydrogen, C1-C6 alkyl, C2-C4 alkenyl, halo, C1-C4 alkoxy, hydroxyl, C6-C14 aryloxy, or C1-C6 alkylhalo group; and
(a) n is 1 or 3-12; or
(b) n is 1-12 and at least one of R1-R5 is not hydrogen.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the delivery agent is selected from 4-(4-methoxyphenyl)butanoic acid, 5-(2-methoxyphenyl)pentanoic acid, 5-(3-fluorophenyl)pentanoic acid, 5-(3-methoxyphenyl)pentanoic acid, 6-(3-fluorophenyl)hexanoic acid, 3-(4-t-butylphenyl)propanoic acid, 3-(4-n-butylphenyl)propanoic acid, 3-(4-n-propylphenyl)propanoic acid, 3-(4-n-propoxyphenyl)propanoic acid, 3-(4-isopropoxyphenyl)propanoic acid, 3-(4-n-Butoxyphenyl)propanoic acid, 3-(3-phenoxyphenyl)propanoic acid, 3-(3-ethoxyphenyl)propanoic acid, 3-(3-isopropoxyphenyl)propanoic acid, 3-(3-n-butoxyphenyl)propanoic acid, 3-(3-n-propoxyphenyl)propanoic acid, 3-(3-isobutoxyphenyl)propanoic acid, 3-(4-isobutoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 4-(4-isopropylphenyl)butanoic acid, and 5-(4-ethylphenyl)pentanoic acid, or pharmaceutically acceptable salts thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The composition of claim 1, wherein the biologically active agent is a protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, lipid, or combination thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the biologically active agent is selected from the group consisting of: argatroban, BIBN-4096BS, growth hormones, human growth hormones recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, glucagon, interferons, α-interferon, β-interferon, γ-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, glucagon-like peptide 1 (GLP-1), antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; gallium or gallium salts; glucagons; zanamivir, sumatriptan, almotriptan, naratriptan, rizatriptan, frovatriptan, eletriptan, caspofungin acetate, CPHPC, siRNA and any combination thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein the biologically active agent is insulin.

### Claim 9

(canceled)

### Claim 10 (depends on 9)

The composition of claim 9, wherein the weight ratio of delivery agent to active agent ranges from about 800:1 to about 10:1.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 1)

A dosage unit form comprising:
(A) a delivery agent according to claim 1; and
(B) a biologically active agent; and
(C) (a) an excipient,
(b) a diluent,
(c) a disintegrant,
(d) a lubricant,
(e) a plasticizer,
(f) a colorant,
(g) an enzyme inhibitor
(h) a dosing vehicle, or
(i) any combination thereof.

### Claim at position 13

15-19. (canceled)

### Claim 20 (depends on 14)

The dosage unit form of claim 14, wherein the dosage unit form comprises a dosing vehicle comprising a tablet, a capsule, a powder, or a liquid.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method for administering a biologically-active agent to an animal in need of the agent, the method comprising administering orally to the animal the composition of claim 1.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method for administering a biologically-active agent to an animal in need of the agent, the method comprising administering to the animal the composition of claim 1 intranasally, sublingually, intraduodenally, subcutaneously, buccally, intracolonicly, rectally, vaginally, mucosally, pulmonary, transdermally, intradermally, parenterally, intravenously, intramuscularly, via the ocular system, or by traversing the blood-brain barrier.

### Claim at position 19

25-30. (canceled)

### Claim 31

A compound selected from the group consisting of 4-(4-methoxyphenyl)butanoic acid, 5-(2-methoxyphenyl)pentanoic acid, 5-(3-fluorophenyl)pentanoic acid, 5-(3-methoxyphenyl)pentanoic acid, 6-(3-fluorophenyl)hexanoic acid, 3-(4-t-butylphenyl) propanoic acid, 3-(4-n-butylphenyl)propanoic acid, 3-(4-n-propylphenyl)propanoic acid, 3-(4-n-propoxyphenyl)propanoic acid, 3-(4-isopropoxyphenyl)propanoic acid, 3-(4-n-butoxyphenyl)propanoic acid, 3-(3-phenoxyphenyl)propanoic acid, 3-(3-ethoxyphenyl)propanoic acid, 3-(3-isopropoxyphenyl)propanoic acid, 3-(3-n-butoxyphenyl)propanoic acid, 3-(3-n-propoxyphenyl)propanoic acid, 3-(3-isobutoxyphenyl)propanoic acid, 3-(4-isobutoxyphenyl)propanoic acid, 4-(4-ethylphenyl)butanoic acid, 4-(4-isopropylphenyl)butanoic acid, and 5-(4-ethylphenyl)pentanoic acid, or pharmaceutically acceptable salts thereof.

### Claim 32 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is methyl, methoxy, C1-C4 alkoxy, hydroxy or halogen.

### Claim 33 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is methyl, methoxy, hydroxy or halogen.

### Claim 34 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is methyl.

### Claim 35 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is methoxy.

### Claim 36 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is hydroxy.

### Claim 37 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is C6-C14 aryloxy.

### Claim 38 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is C1-C4 alkoxy.

### Claim 39 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is C1-C6 alkylhalo.

### Claim 40 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is halogen.

### Claim 41 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is chlorine.

### Claim 42 (depends on 1)

The composition of claim 1, wherein at least one of R1 to R5 is fluorine.
